Recent 8-K filings for KRYS

• May 4, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates

  VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.

• February 17, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111

  Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030

  Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.

• January 8, 2026, 6:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients

  Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).

• November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches

  Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.

• October 22, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit

  Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.

• August 4, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue

  VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.

• July 25, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 7.01item 9.01

  Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa

  Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.

• July 24, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study

  PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.

• July 9, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis

  First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.

• June 2, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%

  27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).

• May 6, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Krystal Biotech Presents Preclinical Data on KB801 Gene Therapy for Neurotrophic Keratitis at ARVO 2025

  KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.

• May 6, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured

  VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.

• April 28, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025

  EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.

• February 28, 2025, 6:59 PM ET regulatory materiality 0.80 positive item 7.01item 9.01

  Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025

  CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.

• February 19, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M

  Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).

• December 18, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC

  ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.

• December 12, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Krystal Biotech reports positive initial clinical data for inhaled gene therapies KB408 (AATD) and KB407 (CF)

  KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.

• November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan

  Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.

• August 28, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté

  94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.

• August 5, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track

  VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.

• May 6, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M

  Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event other_material

23 positive 0 negative 5 neutral

source · KRYS on sec.gov